Literature DB >> 32776150

Loop neochord versus leaflet resection techniques for minimally invasive mitral valve repair: long-term results.

Bettina Pfannmueller1, Martin Misfeld1, Alexander Verevkin1, Jens Garbade1, David M Holzhey1, Piroze Davierwala1, Joerg Seeburger1, Thilo Noack1, Michael A Borger1.   

Abstract

OBJECTIVES: Non-leaflet resection techniques including loop chordal replacement are being used with increasing frequency, but the long-term results of these techniques are still unknown. The aim of this study was to compare the long-term results of loop neochord replacement with leaflet resection techniques in patients undergoing minimally invasive mitral valve (MV) repair for MV prolapse.
METHODS: Between 1999 and 2014, 2134 consecutive MV prolapse patients underwent minimally invasive MV repair with isolated loop (n = 1751; 82.1%) or resection techniques (n = 383, 17.9%) at our institution. Follow-up data were available for 86% of patients with a mean follow-up time of 6.1 ± 4.3 years.
RESULTS: The 30-day mortality was 0.8% for all patients (loop: 0.7%, resection: 1.6%; P = 0.09). Leaflet resection was associated with more moderate or more mitral regurgitation on predischarge echocardiography (P = 0.003). The 1-, 5- and 10-year survival rates were 98 ± 1%, 95 ± 1% and 86 ± 2% for the loop technique versus 97 ± 1%, 92 ± 1% and 81 ± 2% for resection patients, respectively (P = 0.003). Significant predictors for late mortality were MV repair technique (P = 0.004), left ventricular ejection fraction (P < 0.001), age (P < 0.001) and myocardial infarction (P < 0.001). Freedom from MV reoperation at 1, 5 and 10 years was 98 ± 1%, 97 ± 1%, 97 ± 1% and 97 ± 1%, 97 ± 1%, 96 ± 1% for patients operated on with the loop technique and leaflet resection (P = 0.4).
CONCLUSIONS: In our patient cohort, MV repair with loop chordal replacement is associated with less early recurrent mitral regurgitation and very good long-term results when compared to classical leaflet resection techniques for MV prolapse and is therefore an excellent option for such patients.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Long-term results; Minimally invasive mitral valve surgery; Mitral valve repair

Year:  2021        PMID: 32776150     DOI: 10.1093/ejcts/ezaa255

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Biomechanical analysis of neochordal repair error from diastolic phase inversion of static left ventricular pressurization.

Authors:  Matthew H Park; Mateo Marin-Cuartas; Annabel M Imbrie-Moore; Robert J Wilkerson; Pearly K Pandya; Yuanjia Zhu; Hanjay Wang; Michael A Borger; Y Joseph Woo
Journal:  JTCVS Tech       Date:  2022-01-26

2.  Commentary: There are chords in the human heart that had better not be vibrated.

Authors:  Giorgia Bonalumi; Ilaria Giambuzzi; Alessandro Parolari; Michele Di Mauro
Journal:  JTCVS Open       Date:  2021-08-19

3.  Simplifying Mitral Valve Repair: A Guide to Neochordae Reconstruction.

Authors:  Paola Keese Montanhesi; Aly Ghoneim; Jill Gelinas; Michael W A Chu
Journal:  Innovations (Phila)       Date:  2022 Jul-Aug

Review 4.  Surgical mitral valve repair technique considerations based on the available evidence.

Authors:  Tolga Can; Hristo Kirov; Tulio Caldonazo; Murat Mukharyamov; Gloria Färber; Torsten Doenst
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2022-04-27       Impact factor: 0.704

5.  Biomechanical engineering analysis of commonly utilized mitral neochordae.

Authors:  Mateo Marin-Cuartas; Annabel M Imbrie-Moore; Yuanjia Zhu; Matthew H Park; Robert Wilkerson; Matthew Leipzig; Michael A Borger; Y Joseph Woo
Journal:  JTCVS Open       Date:  2021-09-29

6.  Every day mitral valve reconstruction: What has changed over the last 15 years?

Authors:  Farnoosh Motazedian; Roya Ostovar; Martin Hartrumpf; Filip Schröter; Johannes M Albes
Journal:  PLoS One       Date:  2022-10-03       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.